Brief: Cidara Therapeutics Announces Divestiture Of Rezafungin To Mundipharma

Cidara Therapeutics

24/04/2024 21:03

April 24 (Reuters) - Cidara Therapeutics Inc  CDTX.O :
    * CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO
MUNDIPHARMA* TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF
CLOUDBREAK DFC PIPELINE
    * CIDARA THERAPEUTICS INC - TRANSACTION PROVIDES COMPANY
WITH AN
ESTIMATED APPROXIMATELY $128 MILLION
    * CIDARA THERAPEUTICS INC: TO FOCUS ON ADVANCING CLOUDBREAK
DEVELOPMENT PROGRAMS, INCLUDING A PLANNED IND FILING FOR ITS
LEAD ONCOLOGY CANDIDATE, CBO421
    * CIDARA THERAPEUTICS INC - MUNDIPHARMA AGREED TO WAIVE CO'S
OBLIGATION TO REIMBURSE MUNDIPHARMA FOR A $11.145 MILLION
MILESTONE ADVANCE UNDER CONDITIONS

Source text for Eikon:  ID:nGNX717DYJ 
Further company coverage:  CDTX.O 

 (Reuters.Briefs@thomsonreuters.com)